List of Xaracoll drug patents

Xaracoll is owned by Innocoll Pharms.

Xaracoll contains Bupivacaine Hydrochloride.

Xaracoll has a total of 1 drug patent out of which 0 drug patents have expired.

Xaracoll was authorised for market use on 28 August, 2020.

Xaracoll is available in implant;implantation dosage forms.

Xaracoll can be used as a method for inducing a post-surgical analgesia sparing effect by implanting at the surgical site a collagen sponge containing bupivacaine hcl which provides local anesthesia for up to 24 hours following implantation.

The generics of Xaracoll are possible to be released after 20 May, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47826 INNOCOLL PHARMS Drug delivery device for providing local analgesia, local anesthesia or nerve blockage
May, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Aug 28, 2023

Drugs and Companies using BUPIVACAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 August, 2020

Treatment: A method for inducing a post-surgical analgesia sparing effect by implanting at the surgical site a collagen sponge containing bupivacaine hcl which provides local anesthesia for up to 24 hours following implantation

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic